Now more than ever, there is a critical emphasis on minimally invasive procedures for patients seeking gynecologic care. Hologic’s hysteroscopic and laparoscopic suite of solutions was created to arm physicians with innovative and adaptable devices. That’s why at the AAGL 2021 50th Global Congress on minimally invasive gynecologic surgery, we are showcasing the importance of innovation by introducing our new NovaSure® V5 endometrial ablation device and showcasing Acessa® laparoscopic radiofrequency ablation for the first since they joined the Hologic family last year.
Come check us out – both in person and virtually. Meet us at our booth and talk to a representative about the latest advancements in our portfolio and experience our full laparoscopic and hysteroscopic demonstration suites.
Explore the new NovaSure V5 endometrial ablation device and learn how it’s setting the new gold standard in global endometrial ablation (GEA) technology. The NovaSure V5 endometrial ablation device benefits from a number of product improvements, such as the cervical seal featuring EndoForm™ technology designed to increase the sealing surface and accommodate a range of cervical canals and anatomical variability.2,3,4
Meanwhile, AccuSheath™ markings were added to improve the accuracy and confidence of seating and fundal placement.5
And finally, the device is equipped with Hologic’s unique fluid removal system, SureClear™ technology, which provides integrated suction through the array by constant tissue contact while simultaneously removing ablation byproducts such as vapor and fluid from the uterus.¹
At this meeting, you’ll also have a chance to discover the new standard of care for uterine fibroids – laparoscopic radiofrequency ablation (Lap-RFA). Also known as the Acessa procedure, the uterine preserving treatment option provides patient relief with low reintervention.6 The minimally invasive procedure allows for a full view of the pelvic anatomy by simultaneously displaying the laparoscopic camera view and the ultrasound view in real time, unlike many alternative interventions.
Find us at booth 536 and learn more about the Acessa procedure at our symposium Bridging the Gap in Fibroid Treatment Options: Breakfast with the Inventor of Acessa Laparoscopic Radiofrequency Ablation, with Dr. Bruce Lee on November 15th from 6:30-7:45 AM CT. Dr. Lee, will be presented by Dr. Soyini Hawkins, to share his journey of discovery, explain the technology, and use curated case footage to walk through the procedure. Add it to your calendar here!
Not joining in person? Don’t worry – get the full experience by taking a tour around our virtual surgery suite.
Sources:
1. NovaSure V5 Instructions for Use, MAN-07653-001
2. NovaSure V5 cervical seal drawing, FAB-18821
3. Baggish, M.S., Karram, M/M., Atlas of Pelvic Anatomy and Gynecologic Surgery. 4th edition. Elsevier 2016. ISBN: 978-0323225526. Chapter 44, Page 493.
4. Luo, J. et al. Quantitative analyses of variability in normal vaginal shape and dimension on MR images. Int. Urogynecol (2016) 27:1087-1095
5. NovaSure V5 Designs Verification Results, VER-10513
6. Berman JM, Guido RS, Leal JGG, et al. Three-years outcome from the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas. J Minim Invasive Gynecol. 2014;21(5):767-774.
Notes and Disclaimers
IMPORTANT SAFETY INFORMATION NovaSure® endometrial ablation is for premenopausal women with heavy periods due to benign causes who are finished childbearing. Pregnancy following the NovaSure procedure can be dangerous. The NovaSure procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. NovaSure endometrial ablation is not a sterilization procedure. Rare but serious risks include, but are not limited to, thermal injury, perforation and infection. Temporary side effects may include cramping, nausea, vomiting, discharge and spotting. Inform patients to contact you if they experience a possible side effect related to use of this product. For detailed benefit and risk information, please consult the IFU.
IMPORTANT SAFETY INFORMATION The Acessa ProVu system is indicated for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa ProVu system is contraindicated for patients who are not candidates for laparoscopic surgery and/or patients with a uterus adherent to pelvic tissue or viscera. The Acessa ProVu system’s guidance system is not intended for diagnostic use. Please read all instructions for use of the Acessa ProVu system prior to its use. Safe and effective electrosurgery is dependent not only on equipment design but also on factors under control of the operator. Rare but serious risks include, but are not limited to, infection, injury to adjacent structures, blood loss and complications related to laparoscopy and/or general anesthesia. Insufficient data exists on which to evaluate the safety and effectiveness of the Acessa ProVu system in women who plan future pregnancy, therefore the Acessa ProVu system is not recommended for women who are planning future pregnancy.
Dr. Lee and Dr. Hawkins are paid consultants of Hologic. Dr. Lee has a financial interest in the success of the Acessa ProVu system as a result of the acquisition of Acessa Health by Hologic.